| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1052275933 |
| P356 | DOI | 10.2165/00003495-198835050-00003 |
| P8608 | Fatcat ID | release_j7uh2q477fdihdme5oxwt7nram |
| P698 | PubMed publication ID | 2899495 |
| P50 | author | Rex N. Brogden | Q62563651 |
| P2093 | author name string | R A Young | |
| P2860 | cites work | Acute renal effects of doxazosin in man. | Q34446814 |
| Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise | Q34446820 | ||
| A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension | Q34446826 | ||
| The antihypertensive effects of doxazosin: a clinical overview | Q34446834 | ||
| Clinical pharmacological studies with doxazosin | Q34446840 | ||
| Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol | Q34446847 | ||
| Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins | Q34446855 | ||
| Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension | Q34446862 | ||
| The pharmacokinetics of doxazosin in elderly normotensives | Q34447659 | ||
| Effect of propranolol and prazosin on blood lipids. The Oslo Study | Q72425748 | ||
| Prazosin and its analogues UK-18,596 and UK-33,274: a comparative study on cardiovascular effects and alpha-adrenoceptor blocking activities | Q72429905 | ||
| The pharmacology of antihypertensive drugs with special reference to vasodilators, alpha-adrenergic blocking agents and prazosin | Q39169739 | ||
| The pharmacological classification of adrenergic alpha 1 and alpha 2 receptors and their mechanisms of action | Q39290815 | ||
| The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study | Q39433797 | ||
| The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs | Q39460803 | ||
| Mechanism of alpha blockade for blood pressure control | Q39462956 | ||
| The effects of antihypertensive drugs on serum lipids and lipoproteins, I. Diuretics | Q39743407 | ||
| Hepatic vascular bed. | Q40061000 | ||
| The emerging problem of plasma lipid changes during antihypertensive therapy | Q40103502 | ||
| Suppression of renin secretion in the rat kidney by a nonvascular alpha-adrenergic mechanism | Q40251614 | ||
| Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension | Q41761965 | ||
| The alpha 1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology | Q42101154 | ||
| Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man | Q42116080 | ||
| Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension | Q42127517 | ||
| Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists | Q42201649 | ||
| A comparison of the effects of doxazosin and alfuzosin with those of urapidil on preganglionic sympathetic nerve activity in anaesthetised cats | Q42206140 | ||
| Mediation of Renin Release in Essential Hypertension by α-Adrenoreceptors | Q42243100 | ||
| Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist | Q42664441 | ||
| The metabolism and kinetics of doxazosin in man, mouse, rat and dog. | Q43181893 | ||
| A pharmacodynamic and pharmacokinetic assessment of a new alpha- adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects | Q43241370 | ||
| Vascular alpha-adrenoceptors in man: interactions with adrenaline and noradrenaline | Q43535785 | ||
| Doxazosin increases low density lipoprotein receptor activity. | Q43765013 | ||
| Selectivity of benzodioxane alpha-adrenoceptor antagonists for alpha 1- and alpha 2-adrenoceptors determined by binding affinity | Q48857160 | ||
| Effect of Ca2+ blocking agents on the metabolism of low density lipoproteins in human skin fibroblasts. | Q51860265 | ||
| Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. | Q52671776 | ||
| An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension. | Q54136300 | ||
| Clinical pharmacology of doxazosin in patients with essential hypertension. | Q54137765 | ||
| Effect of doxazosin on blood pressure and renal haemodynamics of hypertensive patients with renal failure. | Q54142086 | ||
| Postjunctional Selectivity of α-Blockade with Prazosin, Trimazosin, and UK-33,274 in Man | Q54526678 | ||
| Renal response to propranolol treatment in hypertensive humans | Q54526936 | ||
| Epidemiology of coronary heart disease: the Framingham study. | Q55062740 | ||
| The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in man | Q57403531 | ||
| The Metabolic Fate of Prazosin | Q67066721 | ||
| Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension | Q67693493 | ||
| Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension | Q69000047 | ||
| Differences between exogenous and endogenous noradrenaline in the effects on vascular post-synaptic alpha 1- and alpha 2-adrenoceptors in man | Q69855782 | ||
| Efficacy and safety of doxazosin in hypertension therapy | Q69900508 | ||
| A multicenter trial of doxazosin in West Germany | Q69900510 | ||
| A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension | Q69900529 | ||
| Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin | Q69900531 | ||
| Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension | Q69900534 | ||
| Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure | Q70014856 | ||
| A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension | Q70033587 | ||
| Effect of sympathetic stimulation and intrarenal alpha-blockade on the secretion of renin by the human kidney | Q70100692 | ||
| Identification of vascular postsynaptic alpha 1- and alpha 2-adrenoceptors in man | Q70201024 | ||
| Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection | Q70537765 | ||
| Comparative effects of prazosin and atenolol on plasma lipids in hypertensive patients | Q71286907 | ||
| P433 | issue | 5 | |
| P921 | main subject | arterial hypertension | Q41861 |
| pharmacokinetics | Q323936 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 525-541 | |
| P577 | publication date | 1988-05-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension | |
| P478 | volume | 35 |
| Q33147811 | A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension. |
| Q37608000 | Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism |
| Q40487133 | An Overview of the Pharmacodynamic Properties and Therapeutic Potential of Combined α- and β-Adrenoceptor Antagonists |
| Q39243477 | Antihypertensive drugs interacting with alpha- and beta-adrenoceptors. A review of basic pharmacology |
| Q40708111 | Antihypertensive therapy in the geriatric patient: II. A review of the alpha1-adrenergic blocking agents |
| Q36859820 | Benign prostatic hyperplasia. Practical treatment guidelines |
| Q77952123 | Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group |
| Q36834798 | Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans |
| Q42282267 | Doxazosin versus nitrendipine: a double-blind comparative study in patients adhering to a sodium-restricted diet |
| Q70964336 | Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two) |
| Q40399993 | Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia |
| Q51607749 | Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients |
| Q35803015 | Endocrine and adrenergic pharmacological intervention in diseases of the prostate |
| Q43868885 | Flow injection analysis of doxazosin mesylate using UV-detection |
| Q34707738 | Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs |
| Q35032547 | Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component |
| Q34317675 | Lessons learned from prematurely terminated clinical trials |
| Q44537299 | Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo |
| Q26752782 | Microwave-Assisted Synthesis of Bioactive Six-Membered Heterocycles and Their Fused Analogues |
| Q40071688 | Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest |
| Q37677533 | Newer antihypertensive agents |
| Q38367793 | Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists |
| Q37268536 | Pharmacokinetics of newer drugs in patients with renal impairment (Part II). |
| Q74603170 | Pulse polarographic (constant and increasing) determinations of doxazosin in pharmaceutical tablets |
| Q36648945 | Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction |
| Q37728436 | Stereoselective binding of doxazosin enantiomers to plasma proteins from rats, dogs and humans in vitro |
| Q40755243 | The effect of doxazosin, urapidil and indoramin pretreatment on fever produced by E. coli lipopolysaccharide in rabbits |
| Q42013212 | The potentiation of adrenaline‐induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects |
| Q43620119 | Voltammetric determination of doxazosin in tablets using rotating platinum electrode |
Search more.